Health & Wellness Blog - Page 46

Emcure Revises Poviztra Semaglutide Price to ₹3,999/Month in India

Emcure Pharmaceuticals is slashing the price of Poviztra semaglutide injection to ₹3,999 per month starting April 3, 2026, making this weight management therapy more accessible across India. As the first Indian firm offering this second brand of Novo Nordisk's semaglutide, Emcure aims to tackle the nation's obesity epidemic affecting over 600 million adults. Backed by 49 million patient years and 50 clinical trials, Poviztra promises validated support for obesity-linked conditions.

Shotlee·Apr 3, 2026·5 min read

Telehealth & GLP-1

Entrepreneur Uses AI to Build $1B Telehealth Company on GLP-1 Drugs

Matthew Gallagher, a 41-year-old LA entrepreneur, turned $20,000 into a nearly $2 billion telehealth empire with AI alone. Medvi sells GLP-1 drugs like Ozempic at $300 versus $1,000 retail, serving 250,000 customers. But rapid growth sparks debates on legality and fake ads.

Shotlee·Apr 3, 2026·5 min read

GLP-1 Medications

Wegovy Data Challenges Foundayo, Resets Novo Valuation Debate

Novo Nordisk released new cross-trial data showing its oral Wegovy pill delivers greater weight loss than Eli Lilly's newly FDA-approved Foundayo obesity pill. With fewer adverse events and strong patient preference for Wegovy, this first direct comparison challenges Foundayo's profile. The findings arrive amid volatile CPSE:NOVO B stock performance, resetting valuation debates.

Shotlee·Apr 3, 2026·5 min read

GLP-1 Medications

India's 'Mounjaro Brides': Weight-Loss Injections in Pre-Wedding Prep

In India, 'Mounjaro brides' are using weight-loss injections as part of pre-wedding rituals, driven by intense societal expectations. Clinics like Klarity Skin Clinic offer specialized packages, while doctors report a surge in queries from brides and grooms. This trend highlights both the drugs' popularity and the need for medical supervision.

Shotlee·Apr 3, 2026·5 min read

GLP-1 Medications News

Man Wanted for Stealing £12k Mounjaro After Court No-Show

A 27-year-old man from Wigan is being hunted by police after failing to appear in court on charges of stealing over £12,000 worth of Mounjaro weight loss injections from his workplace. The theft highlights the skyrocketing demand for this GLP-1 medication used for type 2 diabetes and appetite control. Understand the case details and what makes Mounjaro so sought after.

Shotlee·Apr 3, 2026·4 min read

GLP-1 Medications

JD Vance Sparks Ozempic Rumors With Slimmer Appearance

Vice President JD Vance appeared noticeably slimmer in a recent interview with Benny Johnson, igniting Ozempic rumors across X. Netizens speculate on the popular weight-loss drug amid past denials and critic backlash. While no confirmation exists, the buzz highlights Ozempic's role in metabolic health conversations.

Shotlee·Apr 3, 2026·5 min read

Peptide Therapy

Ozempic and Weight-Loss Drugs Create Hidden Waste Disaster

The boom in weight-loss drugs like Ozempic is fueling a hidden environmental crisis, with production generating up to 120 million pounds of toxic solvent waste annually. Traditional solid-phase peptide synthesis relies on hazardous chemicals, but a groundbreaking water-based approach could eliminate this issue. Researchers have demonstrated a cleaner method matching traditional yields.

Shotlee·Apr 2, 2026·4 min read

GLP-1 Medications

Emcure Halves Poviztra Semaglutide Price After Novo Nordisk Patent Expiry

Emcure Pharmaceuticals has halved the price of its semaglutide-based weight loss drug Poviztra after the expiry of Novo Nordisk's patent, making GLP-1 therapy more accessible. Originally developed for diabetes, semaglutide mimics hormones to control appetite and blood sugar, delivering unmatched weight loss results. Check the new rates and learn what this means for patients seeking effective metabolic treatments.

Shotlee·Apr 2, 2026·4 min read

GLP-1 Medications

Emcure Drops Poviztra Semaglutide Starting Dose Price by 55%

Emcure Pharmaceuticals has reduced the price of its semaglutide injection Poviztra by 55% for the starting dose, now at ₹3,999 per month. This move, in partnership with Novo Nordisk, follows recent price slashes on Wegovy and Ozempic and the launch of Indian generics. It aims to tackle India's growing obesity epidemic affecting over 600 million adults.

Shotlee·Apr 2, 2026·5 min read

Latest Articles

Latest Articles

Emcure Revises Poviztra Semaglutide Price to ₹3,999/Month in India

Entrepreneur Uses AI to Build $1B Telehealth Company on GLP-1 Drugs

Wegovy Data Challenges Foundayo, Resets Novo Valuation Debate

India's 'Mounjaro Brides': Weight-Loss Injections in Pre-Wedding Prep

Man Wanted for Stealing £12k Mounjaro After Court No-Show

JD Vance Sparks Ozempic Rumors With Slimmer Appearance

Ozempic and Weight-Loss Drugs Create Hidden Waste Disaster

Emcure Halves Poviztra Semaglutide Price After Novo Nordisk Patent Expiry

Emcure Drops Poviztra Semaglutide Starting Dose Price by 55%

Latest Articles

Emcure Revises Poviztra Semaglutide Price to ₹3,999/Month in India

Entrepreneur Uses AI to Build $1B Telehealth Company on GLP-1 Drugs

Wegovy Data Challenges Foundayo, Resets Novo Valuation Debate

India's 'Mounjaro Brides': Weight-Loss Injections in Pre-Wedding Prep

Man Wanted for Stealing £12k Mounjaro After Court No-Show

JD Vance Sparks Ozempic Rumors With Slimmer Appearance

Ozempic and Weight-Loss Drugs Create Hidden Waste Disaster

Emcure Halves Poviztra Semaglutide Price After Novo Nordisk Patent Expiry

Emcure Drops Poviztra Semaglutide Starting Dose Price by 55%